Nabiev I, Chourpa I, Riou J F, Nguyen C H, Lavelle F, Manfait M
Laboratoire de Spectroscopie Biomoléculaire, UFR de Pharmacie, Université de Reims, France.
Biochemistry. 1994 Aug 2;33(30):9013-23. doi: 10.1021/bi00196a020.
Molecular interactions of intoplicine, dual DNA-topoisomerases (Topo) I and II inhibitor, with topoisomerases, plasmid DNA, in ternary cleavable complexes with enzymes and plasmid DNA, and in the reversed cleavable complexes were examined by means of surface-enhanced Raman scattering (SERS) and CD spectroscopy and by biochemical techniques. Detailed spectral analysis of intoplicine derivatives allowed us to assign SERS vibrational modes of chromophores and to propose the models for these complexes. Intoplicine was found to be able to interact specifically with the Topo II alone, but with Topo I only when in the presence of DNA. It shows at least two modes of binding to the DNA: the first was found to be dominant for its derivative 1c (most potent Topo I inhibitor), and the second was dominant for derivative 2a (most potent Topo II inhibitor). The possibility of forming these two types of complexes simultaneously is suggested to be one of the main factors enabling the drug to be a dual Topo I and Topo II inhibitor. The "deep intercalation mode" of the drug from the DNA minor groove with the long axis of the chromophore oriented roughly parallel to the dyad axis has been suggested to be responsible for induction of distortions of the DNA structure by the intercalating drug. Being involved in the formation of Topo I-mediated cleavable ternary complex, the molecules participating in the deep intercalation mode within the DNA do not change their molecular interactions as compared with their complex with the DNA alone. The stabilization of the Topo I-mediated cleavable complex was shown to be followed by the local denaturation of DNA in the AT-rich regions of the helix. When the ternary cleavable complex was reversed, the drug was shown to be in the complex with the plasmid. The "outside binding mode" from the DNA major groove via the hydroxyl group of the A-ring of the chromophore has been suggested to be responsible for Topo II inhibition. These molecules did not induce significant distortions of the DNA structure. Being involved in the formation of Topo II-mediated cleavable ternary complex, the drug changed its molecular interactions as compared with the complex with DNA alone.(ABSTRACT TRUNCATED AT 400 WORDS)
通过表面增强拉曼散射(SERS)、圆二色光谱(CD)以及生化技术,研究了双DNA拓扑异构酶(Topo)I和II抑制剂英托必辛与拓扑异构酶、质粒DNA在与酶和质粒DNA形成的三元可裂解复合物以及反向可裂解复合物中的分子相互作用。对英托必辛衍生物的详细光谱分析使我们能够确定发色团的SERS振动模式,并提出这些复合物的模型。研究发现,英托必辛能够单独与Topo II特异性相互作用,但只有在存在DNA时才与Topo I相互作用。它显示出至少两种与DNA结合的模式:第一种模式在其衍生物1c(最有效的Topo I抑制剂)中占主导地位,第二种模式在衍生物2a(最有效的Topo II抑制剂)中占主导地位。同时形成这两种类型复合物的可能性被认为是使该药物成为双Topo I和Topo II抑制剂的主要因素之一。药物从DNA小沟以发色团长轴大致平行于二分轴的方式进行“深度嵌入模式”,被认为是嵌入药物诱导DNA结构扭曲的原因。参与Topo I介导的可裂解三元复合物形成时,在DNA内参与深度嵌入模式的分子与单独与DNA形成的复合物相比,其分子相互作用没有改变。结果表明,Topo I介导的可裂解复合物的稳定伴随着螺旋富含AT区域中DNA的局部变性。当三元可裂解复合物逆转时,药物显示与质粒形成复合物。通过发色团A环的羟基从DNA大沟进行的“外部结合模式”被认为是Topo II抑制的原因。这些分子不会诱导DNA结构的显著扭曲。参与Topo II介导的可裂解三元复合物形成时,与单独与DNA形成的复合物相比,药物改变了其分子相互作用。(摘要截断于400字)